Trial reportScientific reports2018
A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity.
Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Efficacy and Safety of Sodium Oxybate in Isolated Focal Laryngeal Dystonia: A Phase IIb Double-Blind Placebo-Controlled Cross-Over Randomized Clinical Trial.Annals of neurology · 2025Trial
- Sodium Oxybate in Alcohol-Responsive Essential Tremor of Voice: An Open-Label Phase II Study.Movement disorders : official journal of the Movement Disorder Society · 2023Trial
- A Comparison of Four Selected Acoustic Measures in Detecting Voice Quality Changes With Botulinum Toxin Treatment in Adductor-Type Laryngeal Dystonia.American journal of speech-language pathology · 2026Article
- Clinical Implications of Dystonia as a Neural Network Disorder.Advances in neurobiology · 2023Review
- Review
- Synaptic effects of ethanol on striatal circuitry: therapeutic implications for dystonia.The FEBS journal · 2022Review
- Short- and Long-term Central Action of Botulinum Neurotoxin Treatment in Laryngeal Dystonia.Neurology · 2022Article
- The Patho-Neurophysiological Basis and Treatment of Focal Laryngeal Dystonia: A Narrative Review and Two Case Reports Applying TMS over the Laryngeal Motor Cortex.Journal of clinical medicine · 2022Review
- Laryngeal Dystonia: Multidisciplinary Update on Terminology, Pathophysiology, and Research Priorities.Neurology · 2021Review
- Alcohol-Responsive Hyperkinetic Movement Disorders-a Mechanistic Hypothesis.Tremor and other hyperkinetic movements (New York, N.Y.) · 2020Review
- A microstructural neural network biomarker for dystonia diagnosis identified by a DystoniaNet deep learning platform.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Mechanisms and Pharmacotherapy for Ethanol-Responsive Movement Disorders.Frontiers in neurology · 2020Review
- Multimodal Quantitative MRI Reveals No Evidence for Tissue Pathology in Idiopathic Cervical Dystonia.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Oral medications for the treatment of dystonia are not established. Currently, symptoms of focal dystonia are managed with botulinum toxin injections into the affected muscles. However, the injection effects are short-lived and not beneficial for all patients. We recently reported significant clinical improvement of symptoms with novel investigational oral drug, sodium oxybate, in patients with the alcohol-responsive form of laryngeal focal dystonia. Understanding the mechanism of action of this promising oral agent holds a strong potential for the development of a scientific rationale for its use in dystonia. Therefore, to determine the neural markers of sodium oxybate effects, which may underlie dystonic symptom improvement, we examined brain activity during symptomatic speech production before and after drug intake in patients with laryngeal dystonia and compared to healthy subjects. We found that sodium oxybate significantly attenuated hyperfunctional activity of cerebellar, thalamic and primary/secondary sensorimotor cortical regions. Drug-induced symptom improvement was correlated with decreased-to-normal levels of activity in the right cerebellum. These findings suggest that sodium oxybate shows direct modulatory effects on disorder pathophysiology by acting upon abnormal neural activity within the dystonic network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.